Fenglong Yu
Overview
Explore the profile of Fenglong Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu F, Chen Q, Hou B
Behav Sci (Basel)
. 2025 Feb;
15(2).
PMID: 40001742
Learning engagement among university students is a critical predictor of academic success. This study, drawing on responses from 333 questionnaires completed by Chinese tourism students, employs the fsQCA method to...
2.
Gu D, Xu D, Yu F, Hou B
PLoS One
. 2024 Feb;
19(2):e0297522.
PMID: 38394092
Although efficiency analysis could reflect the state and quality of tourism's economic development, no research has been conducted investigating the spatiotemporal evolution and mechanisms of county-level tourism efficiency. We quantified...
3.
Chen Q, Zhang Q, Yu F, Hou B
Behav Sci (Basel)
. 2024 Jan;
14(1).
PMID: 38247678
In order to foster students' development and enhance the training quality within tourism programs at universities, this study aims to investigate the relationships among tourism students' professional identity, academic self-efficacy,...
4.
Wang H, Ren B, Liu Y, Jiang B, Guo Y, Wei M, et al.
J Med Chem
. 2020 Dec;
63(24):15541-15563.
PMID: 33264017
Poly (ADP-ribose) polymerase (PARP) plays a significant role in DNA repair responses; therefore, this enzyme is targeted by PARP inhibitors in cancer therapy. Here we have developed a number of...
5.
Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, et al.
Neoplasia
. 2020 Jul;
22(9):431-440.
PMID: 32652442
Pamiparib, an investigational Poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development, demonstrates excellent selectivity for both PARP1 and PARP2, and superb anti-proliferation activities in tumor cell lines with BRCA1/2 mutations...
6.
Ladomersky E, Zhai L, Lenzen A, Lauing K, Qian J, Scholtens D, et al.
Clin Cancer Res
. 2018 Mar;
24(11):2559-2573.
PMID: 29500275
Glioblastoma is the most aggressive primary brain tumor in adults with a median survival of 15-20 months. Numerous approaches and novel therapeutics for treating glioblastoma have been investigated in the...